Osimertinib, a third‐generation TKI, is currently the standard of care as second‐line treatment in patients with T790M‐positive tumors at progression to first‐ or second‐generation EGFR TKI [5] as well as for first‐line treatment of EGFR‐positive NSCLC patients [6]. Here, EGFR is linked to non-small cell lung carcinoma.